AKRO (Akero Therapeutics) Future Price to Earnings

Corporate emblem and logo of Akero Therapeutics Inc (AKRO)

Akero Therapeutics (AKRO) is fighting for survival in a brutal biotech race where the risks of trial failure are extremely high. The potential for premium pricing will allow the company to dictate therapy costs in the future. The company's forward P/E ratio reflects the asset's value dynamics, with the value fixed at 0.00. Expectations for efruxifermin and its status as an attractive acquisition target for pharma behemoths are supporting the rise in share prices.

AKRO - Akero Therapeutics, Inc. Projected Price to Earnings Ratio over the range 07/04/2022 - 12/20/2025

Analytical breakdowns for Akero Therapeutics

- current price and projected stock value:
General company analysis:AKRO akerotx.com
Brand item of Akero Corp

This indicator compares current market capitalization with expected net income, allowing for an assessment of the value of future earnings and preventing false conclusions drawn from one-off quarterly reports. For Akero Therapeutics (AKRO), whose value is based on the success of clinical trials for liver disease drugs, the company's forward P/E ratio history reflects the dynamics of market confidence in the potential of its scientific developments.

Competitors of Akero Therapeutics (AKRO)

Projected Price to Earnings ASND (Ascendis Pharma Inc.)|MDGL (Madrigal Corp) - Future Price to Earnings Multiple|Future Price to Earnings corcept.com CORT|RYTM - Projected Price to Earnings|Metsera Therapeutics - Forward P/E Multiple|Projected Price to Earnings Ratio MoonLake Pharma|CRNX (Crinetics) - Projected Price to Earnings|NAMS: Market Cap to Future Earnings Ratio|SLNO (Soleno Therapeutics Corp) - Forward P/E Multiple|Forward P/E Multiple Amicus Therapeutics|Forward P/E Multiple ETNB|Future Price to Earnings AGIO (Agios)|Future Price to Earnings structuretx.com GPCR|MiMedx Corp (MDXG) - Projected Price to Earnings Ratio|RZLT - Future Price to Earnings|LXRX: Future Price to Earnings|MBX Biosciences, Inc. (MBX) - Future Price to Earnings|ALT - Market Cap to Projected Earnings|Future Price to Earnings Aardvark Pharma|Sagimet Biosciences Inc (SGMT) - Market Cap to Projected Earnings|Future Price to Earnings bioagelabs.com (BIOA)|Projected Price to Earnings Biomea Fusion, Inc. BMEA|Future Price to Earnings Quince QNCX|GUTS (Fractyl Health Inc.) - Price to Expected Earnings Ratio|VTVT: Projected Price to Earnings|Forward Price to Earnings Multiple agapeatpgroup.com (ATPC)|PLUR (Pluri) - Projected Price to Earnings|Price to Future Earnings Ratio SYBX|Future Price to Earnings Lipocine Corporation|matinasbiopharma.com (MTNB) - Market Cap to Projected Earnings|Forward P/E Multiple SPRB|Projected Price to Earnings Galecto, Inc. GLTO|Future Price to Earnings Carmell Corporation CTCX|Future Price to Earnings Multiple LUMO|ONVO: Projected Price to Earnings|Future Price to Earnings Multiple RDUS (Radius Recycling Inc.)